Background: Alport syndrome involves chronic progressive kidney failure and extrarenal organ damage caused by COL4A3, COL4A4, and COL4A5 mutations.
Methods: We initially discerned a COL4A3 splicing mutation via next-generation sequencing. Next, we used bioinformatics, renal biopsy pathology, and an in vitro minigene experiment. Complementary analysis of clinical data was carried out, and we explored the expression and function of the variants to verify their pathogenicity.
Results: A splicing mutation (c.687 + 1G > T) in COL4A3 was found in a Chinese family. Bioinformatics analysis revealed its impact on splicing, causing a translational frameshift, which was confirmed by an in vitro minigene assay. The proband's glomerular basement membrane displayed reduced type IV collagen α3, α4, and α5 chains, with some absent, suggesting disruption of collagen IV trimers in the glomerular basement membrane, potentially damaging the glomerular filtration barrier.
Conclusion: We present a novel finding of a previously unreported c.687 + 1G > T mutation in COL4A3 that disrupts transcription and translation, impairing α3α4α5 (IV) chain formation, altering the integrity of the glomerular basement membrane, causing hereditary Alport syndrome. This discovery enriches the genetic map of Alport syndrome, aiding in clinical genetic guidance, and enhancing the efficacy of prenatal testing.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11807844 | PMC |
http://dx.doi.org/10.1002/mgg3.70053 | DOI Listing |
Mol Med
March 2025
Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen, 518000, Guangdong, China.
X-linked Alport syndrome (XLAS) caused by X-linked COL4A5 gene mutation is a hereditary disease that affects mainly the kidney. XLAS patients, especially males whose single copy of the COL4A5 gene is disrupted, suffer from a life-threatening renal disease, the mechanism of which remains unclear. Renal fibrosis is a characteristic pathology observed in XLAS kidney tissue.
View Article and Find Full Text PDFKidney360
March 2025
Division of Nephrology, Department of Medicine IV, Hospital of the Ludwig-Maximilians-University, Munich, Germany.
Background: Several studies suggest that dietary beta hydroxybutyrate supplementation delays the progression of chronic kidney disease (CKD) by suppressing inflammation and fibrosis. We hypothesized that the oral supplementation with the beta-hydroxybutyrate (BHB) precursor 1,3-butanediol in addition to inhibitors of the renin-angiotensin system (RAS) and sodium-glucose transporter (SGLT)2 would be superior to dual RAS/SGLT2 blockade alone in attenuating the loss of glomerular filtration rate in Col4a3-deficient mice with Alport nephropathy, a spontaneous model of progressive CKD.
Methods: We performed a placebo-controlled study in Col4a3-deficient mice with Alport nephropathy.
Indian J Nephrol
June 2024
Department of Microbiology, All India Institute of Medical Sciences, Patna, Bihar, India.
Zebra bodies are intralysosomal lamellar inclusion bodies. It is accepted as a specific feature of Fabry disease. However, it has been reported in many hereditary and acquired conditions.
View Article and Find Full Text PDFJCI Insight
March 2025
Department of Biochemistry and Molecular & Cellular Biology, Georgetown University, Washington, DC, USA.
Chronic kidney disease (CKD) is associated with renal metabolic disturbances, including impaired fatty acid oxidation (FAO). Nicotinamide adenine dinucleotide (NAD+) is a small molecule that participates in hundreds of metabolism-related reactions. NAD+ levels are decreased in CKD, and NAD+ supplementation is protective.
View Article and Find Full Text PDFSci Rep
March 2025
Department of Medical Genetics, Jiangxi Maternal and Child Health Hospital, Nanchang, China.
Alport syndrome (AS) is the second-most frequent monogenic kidney disease and 85% of cases are caused by mutations in the genes of the α5 chains of collagen type IV (COL4A5). The early diagnosis and treatment are essential for the prognosis of AS. The clinical phenotypes of AS are very variable, which is challenging to diagnose.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!